Quick Answer
Emergent BioSolutions Inc. reported Cash and Equivalents of $99.50 million for fiscal year 2024.
Emergent BioSolutions Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2024 | $99.50M | -10.9% |
| 2023 | $111.70M | -82.6% |
| 2022 | $642.60M | +11.5% |
| 2021 | $576.10M | -7.3% |
| 2020 | $621.30M | +270.3% |
| 2019 | $167.80M | +49.6% |
| 2018 | $112.20M | -37.1% |
| 2017 | $178.30M | -34.3% |
| 2016 | $271.50M | -13.2% |
| 2015 | $312.80M | +11.5% |
| 2014 | $280.50M | +56.4% |
| 2013 | $179.34M | +26.6% |
| 2012 | $141.67M | -1.6% |
| 2011 | $143.90M | -14.9% |
| 2010 | $169.02M | +64.2% |
| 2009 | $102.92M | +12.5% |
| 2008 | $91.47M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $245.50M | +63.8% | -8.2% |
| June 30, 2025 | $267.30M | +283.5% | +79.3% |
| March 31, 2025 | $149.10M | +89.9% | +49.8% |
| December 31, 2024 | $99.50M | -10.9% | -33.6% |
| September 30, 2024 | $149.90M | +70.7% | +115.1% |
| June 30, 2024 | $69.70M | -21.3% | -11.2% |
| March 31, 2024 | $78.50M | -81.8% | -29.7% |
| December 31, 2023 | $111.70M | -82.6% | +27.2% |
- Emergent BioSolutions Inc. showed a decrease of -10.9% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2008–2024 period, Emergent BioSolutions Inc.’s cash and equivalents has grown by 8.8% (from $91.47 million to $99.50 million).
- The most recent figure is from Emergent BioSolutions Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 4, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: